GlassScriptPhysician profile
John Duong
NPI 1407435647
$2,551.33
in general payments reported to CMS, 2019-2025
21 companies · $975 in 2025
The $975 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $418 · 2024: $1,158 · 2025: $975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,551.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $832.67 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $359.70 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $295.51 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $225.40 | 2024-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $177.72 | 2023-2025 | Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.87 | 2023-2025 | Xifaxan |
| Pfizer INC. | $111.29 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $71.53 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Abbvie INC. | $62.50 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.63 | 2024 | |
| Esperion Therapeutics, INC. | $44.74 | 2024-2025 | Nexletol |
| Sumitomo Pharma America, INC. | $31.66 | 2025 | Gemtesa |
| Exact Sciences Corporation | $31.33 | 2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $20.98 | 2025 | Korlym |
| Actelion Pharmaceuticals US, INC. | $20.61 | 2024 | Uptravi, Opsumit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $18.74 | 2024 | |
| Shield Therapeutics INC | $18.47 | 2025 | |
| Inari Medical, INC. | $16.58 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boston Scientific Corporation | $16.23 | 2024 | Watchman Flx |
| Nevro Corp. | $15.70 | 2024 | Senza |
| Xeris Pharmaceuticals, INC. | $14.47 | 2025 | Keveyis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Duong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.